Pharmaceutical Industry News
As part of the agreement, SCT and NexGen will license their respective technologies to ReNeu under world-wide, royalty-free licenses for the use of NexGen's FDA-cleared EViTAR line of proprietary intracranial delivery systems and SCT's NTx-265, -428...